The study investigates the possibility that levetiracetam may improve the symptoms of chronic post-stroke aphasia.
In the study, 50 post-stroke subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design.
- Levetiracetam (Levetiracetam)Drug
Other Names: Keppra Intervention Desc: subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design ARM 1: Kind: Experimental Label: Treatment first Description: Levitiracetam is started immediately after baseline data is collected. ARM 2: Kind: Experimental Label: Wait control Description: Levitiracetam is started after a delay.
- Allocation: Non-Randomized
- Masking: Open Label
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Crossover Assignment
50 post-stroke subjects with aphasia will take levetiracetam(Keppra) in an ABAB(A-On medication and B-Off Medication ) design and will undergo speech, language, and memory evaluations every 6 weeks.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Speech and language assessment.|
|Primary||Speech and language assessment||6 months - 1year||No|
|Secondary||Memory assessment||6 months to 1 year||No|